The best Side of HOIPIN-1
MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre review to evaluate various intravenous doses of sifalimumab, in adult patients with dermatomyositis or polymyositis (NCT00533091). Key trial goals were to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis sufferers,